BiomX discontinues Phase 2b BX004 cystic fibrosis trial and refocuses on BX011

BiomX announced on December 8, 2025 that it was discontinuing its Phase 2b trial of BX004 in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, saying the time and resources needed for the alternative dosing strategy recommended by its Data Monitoring Committee exceeded its available resources. The company is cutting costs, including a significant workforce reduction, and will focus on its phage therapeutic BX011 for diabetic foot infections while reviewing strategic alternatives.